Maravai LifeSciences Holdings, Inc.
MRVI
$4.15
-$0.14-3.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 40.53% | -11.83% | -39.69% | -31.73% | -27.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.53% | -11.83% | -39.69% | -31.73% | -27.00% |
| Cost of Revenue | -17.86% | -4.96% | -2.22% | 2.71% | 2.06% |
| Gross Profit | 336.26% | -25.00% | -82.46% | -74.81% | -70.11% |
| SG&A Expenses | -26.47% | -26.33% | -9.44% | -4.88% | -3.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.09% | -16.24% | -6.66% | -1.16% | -0.80% |
| Operating Income | 101.96% | 25.69% | -190.60% | -143.79% | -82.97% |
| Income Before Tax | 87.61% | -36.76% | 73.77% | -255.43% | -135.13% |
| Income Tax Expenses | -193.21% | 185.71% | -129.58% | -76.10% | -40.22% |
| Earnings from Continuing Operations | 87.93% | -36.79% | 73.87% | -279.14% | -133.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -88.46% | 35.57% | -74.13% | 250.43% | 116.07% |
| Net Income | 87.53% | -37.74% | 73.67% | -304.44% | -147.93% |
| EBIT | 101.96% | 25.69% | -190.60% | -143.79% | -82.97% |
| EBITDA | 150.37% | 48.85% | -5,497.09% | -917.71% | -185.15% |
| EPS Basic | 87.79% | -34.65% | 74.25% | -280.72% | -128.70% |
| Normalized Basic EPS | 115.92% | 2,855.17% | -106.21% | 155.41% | 50.00% |
| EPS Diluted | 87.79% | -34.65% | 74.25% | -280.72% | -128.70% |
| Normalized Diluted EPS | 115.92% | 2,855.17% | -106.21% | 155.41% | 50.00% |
| Average Basic Shares Outstanding | 2.09% | 2.30% | 2.21% | 6.18% | 8.38% |
| Average Diluted Shares Outstanding | 2.09% | 2.30% | 2.21% | 6.18% | 8.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |